Halozyme Therapeutics, Inc.
HALO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $8,597 | $6,312 | $7,862 | $6,043 |
| - Cash | $420 | $62 | $176 | $116 |
| + Debt | $1,511 | $1,509 | $1,507 | $1,506 |
| Enterprise Value | $9,688 | $7,760 | $9,193 | $7,433 |
| Revenue | $354 | $326 | $265 | $298 |
| % Growth | 8.8% | 23% | -11.1% | – |
| Gross Profit | $299 | $279 | $216 | $256 |
| % Margin | 84.4% | 85.8% | 81.7% | 85.9% |
| EBITDA | $285 | $230 | $169 | $203 |
| % Margin | 80.3% | 70.6% | 63.7% | 68.2% |
| Net Income | $175 | $165 | $118 | $137 |
| % Margin | 49.5% | 50.7% | 44.6% | 46% |
| EPS Diluted | 1.43 | 1.33 | 0.93 | 1.06 |
| % Growth | 7.5% | 43% | -12.3% | – |
| Operating Cash Flow | $179 | $100 | $154 | $178 |
| Capital Expenditures | -$3 | -$2 | -$1 | -$3 |
| Free Cash Flow | $176 | $98 | $153 | $175 |